Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
Keywords: Docetaxel, elderly patients, nab-paclitaxel, paclitaxel, squamous cell carcinoma
AbstractBased on demonstrated favourable risk–benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc s ubtypes. I n 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxel–carboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.
How to Cite
Socinski, M. (2014). Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Current Oncology, 21(5), e691-e703. https://doi.org/10.3747/co.21.1997